BACKGROUND: Data regarding real-life effectiveness of any treatment may improve clinical decision-making. The aim of this study was to evaluate real-life effectiveness of tyrosin-kinase inhibitors, bevacizumab and pemetrexed as first-line treatments in patients with advanced/metastatic non-small cell lung cancer (NSCLC). METHODS: We analyzed data of 2157 patients of the Czech TULUNG Registry of patients with advanced/metastatic NSCLC who received modern-era treatments between 2011 and 2018. Patients treated with gefitinib, erlotinib, afatinib, bevacizumab (+ maintenance), pemetrexed (+ maintenance) as first-line therapy were included in the study. A systematic literature search separately identified clinical trials suitable for calculation of comparator pooled OS and PFS for each regimen. For each subgroup, basic characteristics and survival data (Kaplan-Meier estimates) are shown. We propose the "index of real-life effectiveness" (IRE), a ratio of real-life OS/PFS and comparator pooled OS/PFS. Univariate and multivariate logistic regression identified factors were associated with longer OS (ie, IRE>1.1). RESULTS: Survival analysis showed median OS of 23 months for erlotinib, 29.3 months for afatinib, 19.6 months for gefitinib, 12.2 months for pemetrexed, 17.5 months for pemetrexed maintenance, 15.8 months for bevacizumab and 15.8 months for bevacizumab maintenance. Calculated IREs for OS for the regimens were: erlotinib 1.013, afatinib 1.184, gefitinib 0.736, pemetrexed 1.188, pemetrexed maintenance 1.294, bevacizumab 1.178, and bevacizumab maintenance 1.189. Multivariate regression analysis showed that these factors were associated with longer OS: lower PS for afatinib; lower PS, absence of adverse events and female sex for bevacizumab; and lower PS and female sex for pemetrexed. CONCLUSIONS: This study clearly demonstrated that real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems, and comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens. Lower ECOG PS, younger age, female sex and adverse events were associated with longer survival in most regimens. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Comparison between TULUNG data and pooled survival data from trials showed higher real-life effectiveness for most of the studied first-line regimens; for most regimens, lower ECOG PS, younger age, female sex and adverse events were associated with longer survival. WHAT THIS STUDY ADDS: Real-life effectiveness of certain treatment regimens may strongly differ in various populations/health care systems.

1st Faculty of Medicine Charles University Prague Czech Republic

2nd Faculty of Medicine Charles University Prague Czech Republic

Clinic of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology General Teaching Hospital Prague Czech Republic

Department of Pneumology and Thoracic Surgery Bulovka Hospital Prague Czech Republic

Department of Pneumology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Pneumology University Hospital Motol Prague Czech Republic

Department of Pneumology University Hospital Pilsen Pilsen Czech Republic

Department of Respiratory Diseases University Hospital Brno Brno Czech Republic

Department of Respiratory Medicine Thomayer Hospital Prague Czech Republic

Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic

Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Faculty of Medicine Charles University Prague Pilsen Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine Palacky University Olomouc Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Zobrazit více v PubMed

Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol 2018; 13: 301–22. PubMed

Bratova M, Karlinova B, Skrickova J et al Non‐small cell lung cancer as a chronic disease ‐ a prospective study from the Czech TULUNG registry. In Vivo 2020; 34: 369–79. PubMed PMC

Cramer‐van der Welle CM, Schramel FMNH, van Leeuwen AS, Groen HJM, van de Garde EMW, for the Santeon NSCLC Study Group . Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. Eur Respir J 2019; 54 (suppl 63): PA374. PubMed PMC

Bonotto M, Gerratana L, Iacono D et al Treatment of metastatic breast cancer in a real‐world scenario: Is progression‐free survival with first line predictive of benefit from second and later lines? Oncologist 2015; 20: 719–24. PubMed PMC

Cramer‐van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW for the Santeon NSCLC study group . Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J 2018; 52: 1801100. PubMed PMC

Lakdawalla DN, Shafrin J, Hou N et al Predicting real‐world effectiveness of cancer therapies using overall survival and progression‐free survival from clinical trials: Empirical evidence for the ASCO value framework. Value Health 2017; 20: 866–75. PubMed

Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real‐life patients with COPD for inclusion in trials of inhaled long‐acting bronchodilator therapy. Respir Res 2016; 17: 120. PubMed PMC

Kawachi H, Fujimoto D, Morimoto T et al Clinical characteristics and prognosis of patients with advanced non‐small‐cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer 2018; 19: e721–34. PubMed

Goldstraw P, Groome P. Lung and pleural tumours In: Sobin LH, Gospodarowicz MK, Wittekind C. (eds). UICC TNM Classification of Malignant Tumours, 7th edn Wiley‐Blackwell, Hoboken, NJ: 2009; 136–46.

Eisenhauer EA, Therasse P, Bogaerts J et al New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2): 228–47. PubMed

Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M. Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high‐grade gliomas. Medicine 2017; 96: e8293. PubMed PMC

International Agency for Research on Cancer . The Netherlands. Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/populations/528-the-netherlands-fact-sheets.pdf

Koopman JJ, Putter H. Regional variation in the practice of euthanasia and physician‐assisted suicide in The Netherlands. Neth J Med 2016; 74: 387–94. PubMed

Pardon K, Deschepper R, Vander Stichele R et al Expressed wishes and incidence of euthanasia in advanced lung cancer patients. Eur Respir J 2012; 40: 949–56. PubMed

Bergqvist M, Christensen HN, Wiklund F, Bergström S. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010‐2016 in Sweden: A nationwide observational study. Int J Cancer 2020; 146: 2510–7. PubMed

Sun JM, Oh DY, Lee SH et al The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non‐small cell lung cancer. Lung Cancer 2010; 68: 427–32. PubMed

Ciuleanu T, Brodowicz T, Zielinski C et al Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non‐small‐cell lung cancer: A randomised, double‐blind, phase 3 study. Lancet 2009; 374: 1432–40. PubMed

Paz‐Ares LG, de Marinis F, Dediu M et al PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2013; 31: 2895–902. PubMed

Ramalingam SS, Dahlberg SE, Belani CP et al Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non‐small‐cell lung cancer: ECOG‐ACRIN 5508. J Clin Oncol 2019; 37: 2360–7. PubMed PMC

Zinner RG, Obasaju CK, Spigel DR et al PRONOUNCE: Randomized, open‐label, phase III study of first‐line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non‐small‐cell lung cancer. J Thorac Oncol 2015; 10: 134–42. PubMed PMC

Grønberg BH, Bremnes RM, Fløtten O et al Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first‐line chemotherapy in advanced non‐small‐cell lung cancer. J Clin Oncol 2009; 27: 3217–24. PubMed

Park CK, Oh IJ, Kim KS et al Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first‐line treatment of nonsquamous non‐small‐cell lung cancer: A TRAIL trial. Clin Lung Cancer 2017; 18: e289–96. PubMed

Paz‐Ares L, Mezger J, Ciuleanu TE et al Necitumumab plus pemetrexed and cisplatin as first‐line therapy in patients with stage IV non‐squamous non‐small‐cell lung cancer (INSPIRE): An open‐label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16: 328–37. PubMed

Rodrigues‐Pereira J, Kim JH, Magallanes M et al A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first‐line treatment for advanced, nonsquamous non‐small cell lung cancer. J Thorac Oncol 2011; 6: 1907–14. PubMed

Scagliotti GV, Parikh P, von Pawel J et al Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008; 26: 3543–51. PubMed

Reck M, von Pawel J, Zatloukal P et al Overall survival with cisplatin‐gemcitabine and bevacizumab or placebo as first‐line therapy for nonsquamous non‐small‐cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804–9. PubMed PMC

Sandler A, Gray R, Perry MC et al Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer. N Engl J Med 2006; 355: 2542–50. PubMed

Zhou C, Wu YL, Chen G et al BEYOND: A randomized, double‐blind, placebo‐controlled, multicenter, phase III study of first‐line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2015; 33: 2197–204. PubMed

Patel JD, Socinski MA, Garon EB et al PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2013; 31: 4349–57. PubMed PMC

Johnson BE, Kabbinavar F, Fehrenbacher L et al ATLAS: Randomized, double‐blind, placebo‐controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first‐line treatment of advanced non‐small‐cell lung cancer. J Clin Oncol 2013; 31: 3926–34. PubMed

Camerini A, Chella A, Mazzoni F et al First‐line treatment of NSCLC with bevacizumab: Real world data from an Italian regional based survey. J Chemother 2017; 29: 38–41. PubMed

Chang GC, Ahn MJ, Wright E et al Comparative effectiveness of bevacizumab plus cisplatin‐based chemotherapy versus pemetrexed plus cisplatin treatment in east Asian non‐squamous non‐small cell lung cancer patients applying real‐life outcomes. Asia Pac J Clin Oncol 2011; 7 (Suppl 2): 34–40. PubMed

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and safety of afatinib for EGFR‐mutant non‐small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat 2019; 51: 502–9. PubMed PMC

Yoshioka H, Shimokawa M, Seto T et al Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first‐line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation‐positive non‐small‐cell lung cancer. Ann Oncol 2019; 30: 1978–84. PubMed

Mok TS, Cheng Y, Zhou X et al Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non‐small‐cell lung cancer and EGFR‐activating mutations. J Clin Oncol 2018; 36: 2244–50. PubMed

Hosomi Y, Morita S, Sugawara S et al North‐East Japan study group. Gefitinib alone versus gefitinib plus chemotherapy for non‐small‐cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 2020; 38: 115–23. PubMed

Yao ZH, Liao WY, Ho CC et al Real‐world data on prognostic factors for overall survival in EGFR mutation‐positive advanced non‐small cell lung cancer patients treated with first‐line gefitinib. Oncologist 2017; 22: 1075–83. PubMed PMC

Maguire FB, Morris CR, Parikh‐Patel A et al First‐line systemic treatments for stage IV non‐small cell lung cancer in California: Patterns of care and outcomes in a real‐world setting. JNCI Cancer Spectr 2019; 3: pkz020. PubMed PMC

von Verschuer U, Schnell R, Tessen HW et al Treatment, outcome and quality of life of 1239 patients with advanced non‐small cell lung cancer ‐ final results from the prospective German TLK cohort study. Lung Cancer 2017; 112: 216–24. PubMed

Park K, Tan EH, O'Byrne K et al Afatinib versus gefitinib as first‐line treatment of patients with EGFR mutation‐positive non‐small‐cell lung cancer (LUX‐lung 7): A phase 2B, open‐label, randomised controlled trial. Lancet Oncol 2016; 17: 577–89. PubMed

Wu YL, Zhou C, Hu CP et al Afatinib versus cisplatin plus gemcitabine for first‐line treatment of Asian patients with advanced non‐small‐cell lung cancer harbouring EGFR mutations (LUX‐lung 6): An open‐label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213–22. PubMed

Wu YL, Zhou C, Liam CK et al First‐line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer: Analyses from the phase III, randomized, open‐label, ENSURE study. Ann Oncol 2015; 26: 1883–9. PubMed

Zhou C, Wu YL, Chen G et al Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first‐line treatment of EGFR mutation‐positive advanced non‐small‐cell lung cancer (OPTIMAL, CTONG‐0802). Ann Oncol 2015; 26: 1877–83. PubMed

An C, Zhang J, Chu H et al Study of gefitinib and pemetrexed as first‐line treatment in patients with advanced non‐small cell lung cancer harboring EGFR mutation. Pathol Oncol Res 2016; 22: 763–8. PubMed

Han B, Jin B, Chu T et al Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Int J Cancer 2017; 141: 1249–56. PubMed

Han JY, Park K, Kim SW et al First‐SIGNAL: First‐line single‐agent iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122–8. PubMed

Inoue A, Kobayashi K, Maemondo M et al Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin‐paclitaxel for chemo‐naïve non‐small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54–9. PubMed

Maemondo M, Inoue A, Kobayashi K et al Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8. PubMed

Patil VM, Noronha V, Joshi A et al Phase III study of gefitinib or pemetrexed with carboplatin in EGFR‐mutated advanced lung adenocarcinoma. ESMO Open 2017; 2: e000168. PubMed PMC

Zhou C, Wu YL, Chen G et al Erlotinib versus chemotherapy as first‐line treatment for patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer (OPTIMAL, CTONG‐0802): A multicentre, open‐label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–42. PubMed

Rosell R, Carcereny E, Gervais R et al Spanish lung cancer group in collaboration with Groupe Français de Pneumo‐Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first‐line treatment for European patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer (EURTAC): A multicentre, open‐label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–46. PubMed

Nakagawa K, Garon EB, Seto T et al Ramucirumab plus erlotinib in patients with untreated, EGFR‐mutated, advanced non‐small‐cell lung cancer (RELAY): A randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol 2019; 20: 1655–69. PubMed

Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A phase III, randomized, open‐label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non‐small‐cell lung cancer. Ann Oncol 2019; 30: 1127–33. PubMed PMC

Mitsudomi T, Morita S, Yatabe Y et al West Japan oncology group. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8. PubMed

Mok TS, Wu YL, Thongprasert S et al Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57. PubMed

Wu YL, Cheng Y, Zhou X et al Dacomitinib versus gefitinib as first‐line treatment for patients with EGFR‐mutation‐positive non‐small‐cell lung cancer (ARCHER 1050): A randomised, open‐label, phase 3 trial. Lancet Oncol 2017; 18: 1454–66. PubMed

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer